Takeda takes the lead on Finch’s ulcerative colitis candidate FIN-524
The clinical development programme is now known as TAK-524
Read More
Tag: Finch Therapeutics
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
